Q4 2024

Source filing unavailable

Q4 2024 · —

derived · Computed from the longer spans the company filed.

Revenue—

Net Income

-$884.74K

derivedno prior Q4 2023 on file

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Cash Flowderived-$1,077,145—

Same quarter

no prior Q4 2023 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Clearmind Medicine Inc. · CIK 1892500 · Engraved from SEC EDGAR